Revtorpyk is a drug owned by Celcuity Inc. It is protected by 7 US drug patents filed in 2026 out of which none have expired yet. Revtorpyk's patents will be open to challenges from 14 July, 2030. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 31, 2042. Details of Revtorpyk's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US8039469 | Triazine Compounds As Pi3 Kinase And Mtor Inhibitors |
Dec, 2029
(3 years from now) | Active |
| US9174963 | Triazine Compounds As Pi3 Kinase And Mtor Inhibitors |
May, 2029
(2 years from now) | Active |
| US8575159 | Triazine Compounds As Pi3 Kinase And Mtor Inhibitors |
May, 2029
(2 years from now) | Active |
| US8748421 | Triazine Compounds As P13 Kinase And Mtor Inhibitors |
May, 2029
(2 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12350276 | Methods For The Treatment Of Cancer Using 1-(4-{[4-(Dimethylamino)Piperidin-1-Yl]Carbonyl}Phenyl)-3-[4-(4,6-Dimorpholin-4-Yl-1,3,5-Triazin-2-Yl)Phenyl]Urea |
Aug, 2042
(15 years from now) | Active |
| US12109308 | Aqueous Formulation Comprising 1-(4-{[4-(Dimethylamino)Piperidin-1-Yljcarbonyl}Phenyl)-3-[4-(4,6-Dimorpholin-4-Yl-1,3,5-Triazin-2-Yl)Phenyl]Urea |
Jan, 2041
(14 years from now) | Active |
| US8217036 | Triazine Compounds As Pi3 Kinase And Mtor Inhibitors |
May, 2029
(2 years from now) | Active |
FDA has granted several exclusivities to Revtorpyk. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Revtorpyk, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Revtorpyk.
Exclusivity Information
Revtorpyk holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2031. Details of Revtorpyk's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 14, 2031 |
US patents provide insights into the exclusivity only within the United States, but
Revtorpyk is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Revtorpyk's family patents as well as insights into
ongoing legal events
on those patents.
Revtorpyk's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Revtorpyk's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Aug 31, 2042 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Revtorpyk Generics:
There are no approved generic versions for Revtorpyk as of now.
About Revtorpyk
Revtorpyk is a drug owned by Celcuity Inc. Revtorpyk uses Gedatolisib as an active ingredient. Revtorpyk was launched by Celcuity in 2026.
Approval Date:
Revtorpyk was approved by FDA for market use on 14 July, 2026.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Revtorpyk is 14 July, 2026, its NCE-1 date is estimated to be 14 July, 2030.
Active Ingredient:
Revtorpyk uses Gedatolisib as the active ingredient. Check out other Drugs and Companies using Gedatolisib ingredient
Dosage:
Revtorpyk is available in powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 180MG/VIAL | POWDER | Prescription | INTRAVENOUS |
